GUANGZHOU HANFANG PHARMACEUTICAL COMPANY LIMITED

Guangzhou Pharmaceutical Holdings Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. is a subsidiary of Guangzhou Pharmaceutical Holdings, China’s largest pharmaceutical group. It was formed through the merger of the former Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. and Guangzhou Huanye Pharmaceutical Co., Ltd. With registered capital of RMB 169 million, it is a high-tech pharmaceutical manufacturing enterprise focused on the production and development of natural medicines, phytochemical APIs, traditional Chinese medicines, chemical pharmaceutical preparations, and health products made from natural raw materials. Supported by extraction and separation technologies and chemical synthesis technologies as its core strengths, the company focuses on the research and development of three major categories in extraction and separation processes—traditional Chinese medicine extraction, separation and purification, and process quality control—and eight technologies: supercritical CO2 extraction, tank-group dynamic countercurrent extraction, macroporous resin adsorption separation, molecular distillation, high-speed countercurrent chromatography, membrane separation, near-infrared online detection and fingerprint control for extraction and separation processes, and integrated optimization technologies for extraction and separation processes. The company has nearly 300 employees. It owns an 1,800 m2 first-class domestic traditional Chinese medicine R&D laboratory aligned with international standards, 2,800 m2 pilot-scale and small-scale workshops for new extraction and separation technologies and a formulation pilot workshop, a 62,000 m2 national high-tech industrialization demonstration base for modern traditional Chinese medicine extraction and separation, and a 20,000 m2 GMP production workshop for APIs and preparations. Its API workshop has passed audits by multiple multinational companies and is currently applying for U.S. FDA certification and EU COS certification. In the next 3 to 5 years, Hanfang Company will strive to become a national source of innovation for new products and engineering technologies in the traditional Chinese medicine industry, and advanced technologies...